Global Hepatitis Therapeutics Market Outlook to 2025, Key Disease Type (Hepatitis A, B, C, D, E), Key Product Categories (Medications and Vaccines), Regional Segmentation, Pricing Analysis, Pipeline Analysis, Competitive Dynamics, M&A Insights, Regulatory Landscape, Segment Forecast and Conclusion

$3,650.00$6,650.00

Clear
  • Report Description
  • Table of Content
  • Highlight
  • Research Methodology
  • Request Free Sample

The Global Hepatitis Therapeutic market was valued at $ 23.4 Billion in 2017 and is forecast to grow at a modest 3.6 % CAGR between 2018 and 2025, culminating in 2025 global sales of $ 27.8 Billion. Rising viral infection including type A, B, C, D, E and possible G are major cause of hepatitis. Hepatis B and C can cause chronic hepatitis. Symptoms of acute hepatitis A include fatigue, flu like conditions or dark urine where as chronic hepatitis are mild and non-specific.

 

As per Center for Disease Control (CDC), in 2017 reported cases of hepatitis C nearly tripled, reaching 15 years high. Actually 10 times more patients get undetected. Similarly, 1,390 new patients reported with Hepatitis A and 3,370 new cases of Hepatitis B in 2015. We are observing steep rise in cases of hepatitis C in particular in last few years and trend is going to continue. Patients with autoimmune disorder are adding to increase prevalence of hepatitis. Aging population and changing societal behavior adding to this steady increase. Globally, in 2015, an estimated 257 million people were living with chronic HBV infection, and 71 million people with chronic HCV infection.

 

We are observing increasing deaths due to viral hepatitis globally, 1.34 million deaths in 2015, comparable to deaths caused by tuberculosis and higher than those caused by HIV. However, the number of deaths due to viral hepatitis is increasing over time, while mortality caused by tuberculosis and HIV is declining.

 

Global Hepatitis Therapeutic Market to 2025

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Global Hepatitis Therapeutics Products”

 

Estimated Average Hepatitis Therapeutics product cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the world, the Hepatitis Therapeutics products are available at USD XXXX. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.

 

Treatment Insight

 

Hepatitis A- It’s a short-term illness and may not require any medication apart from bed rest and physician order for hydration and nutrition. Hepatitis A vaccine is also available to prevent infection.

Hepatitis B- It’s treated with antiviral medications. These treatments are supposed to continue for several months. It also requires regular physician supervision to ensure if the virus is responding to the treatment. Hepatitis B vaccination available recommended for all newborns.

Hepatitis C- Antiviral medications are usually recommended for the treatment of hepatitis C. Currently there is no vaccination for Hepatitis C.

Hepatitis D- No antiviral medications for the treatment of hepatitis D. Limited improvement noticed with fewer patients with a drug called alpha interferon. It can also prevent by vaccination for Hepatitis B.

Hepatitis E- No specific medication for hepatitis E apart from sufficient rest, water and nutrients.

Some of the U.S. FDA recommended antiviral medicines for the treatment of hepatitis B are as below-

 

Hepatitis B Therapeutic

 

Some of the U.S. FDA recommended antiviral medicines for the treatment of hepatitis C are as below-

 

Hepatitis C Therapeutic

 

We have segmented the market based on the type of hepatitis as Hepatitis A, B, C, D, E, and others.

 

Product Insight

 

We have segmented the market based on medications and vaccines. We will help our client in understanding market segment for individual treatment type if necessary at a premium service.

 

Regional Segmentation

 

North America accounted for over xx% revenue share in 2017. The key reasons attributed to the high share include strong reimbursement framework, technological advancements and government support for R&D and innovation in medical devices sector. Moreover, the presence of high-end hospital and POC and high emphasis on prevention is expected to boost the usage rates over the forecast period.

Asia Pacific is expected to register the maximum CAGR of xx% from 2017 to 2025. The rapid increase in a number of chronic cases, growing healthcare expenditure and skill training, and improvement in reimbursement scenario are expected to favor the high market growth in the region.

 

Top Players & Company Share

 

We have profiled major players in the market as Sanofi, GSK, Merck & Co., Roche, Bristol-Myers Squibb Company, Gilead, Vertex Pharmaceuticals, Three Rivers Pharma, Schering, Janssen Pharmaceuticals, Schering, Gilead Sciences, Merck Sharp Dohme. With recent development, we are observing some unique new players into the market.

 

Market Segmentation

 

Global Hepatitis Therapeutics Market by Disease Types (Revenue, USD Million, 2014- 2025)

  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Hepatitis D
  • Hepatitis E
  • Others

Global Hepatitis Therapeutics Market by Products (Revenue, USD Million, 2014 – 2025)

  • Medications
  • Vaccines

Global Hepatitis Therapeutics Systems Regional Outlook (Revenue, USD Million, 2014- 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • South Africa

Chapter 1 Methodology and Scope

  • Research Methodology
  • Research Scope & Assumptions
  • List of Data Sources

Chapter 2 Executive Summary

Chapter 3 Hepatitis Therapeutics Market Overview

  • Disease Landscape
  • Healthcare Expenditure

Chapter 4 Hepatitis Therapeutics Market Industry Outlook

  • Market Overview
  • Market Segmentation
  • Market Size and Growth Prospects
  • Leading Brand Dynamics
  • Major Buying Authorities and Decision-Making Process
  • Key Market Driver
    • Rising infection through infected needle
    • Aging population
    • Increasing cases of autoimmune disorder and HIV
    • Availability of new treatment options
  • Key market restraint analysis
    • Non-detection of hepatitis B and C
    • Lack of skilled professionals
  • Key Opportunities Prioritized
  • Company Market Share/Heat Map Analysis
  • Industry Analysis – Porter’s
  • Hepatitis Therapeutics Market-PESTEL Analysis

Chapter 5: - Hepatitis Therapeutics Market by “Disease” (USD Million)

  • Hepatitis Therapeutics Market Landscape by Disease Type- 2014 & 2025
  • Hepatitis A
  • Market Landscape Analysis, 2014-2025 (USD Mn)
  • Hepatitis B
  • Market Landscape Analysis, 2014-2025 (USD Mn)
  • Hepatitis C
  • Market Landscape Analysis, 2014-2025 (USD Mn)
  • Hepatitis D
  • Market Landscape Analysis, 2014-2025 (USD Mn)
  • Hepatitis E
  • Market Landscape Analysis, 2014-2025 (USD Mn)
 

Chapter 6: - Hepatitis Therapeutics Market by “Product” (USD Million)

  • Hepatitis Therapeutics Market Landscape by Product Type- 2014 & 2025
  • Medications
  • Market Landscape Analysis, 2014-2025 (USD Mn)
  • Vaccines
  • Market Landscape Analysis, 2014-2025 (USD Mn)
 

Chapter 7: Regional Segmentation Market Outlook

  • Hepatitis Therapeutics Market Landscape by Region- 2017
  • North America Market Landscape Analysis, 2017-2025 (USD Mn)
    • U.S. Market Landscape Analysis, 201-2025
    • Canada Market Landscape Analysis-2017-2025
  • Europe Market Landscape Analysis, 2017-2025 (USD Mn)
    • UK Market Landscape Analysis, 2017-2025
    • Germany Market Landscape Analysis, 2017-2025
    • France Market Landscape Analysis, 2017-2025
    • Italy Market Landscape Analysis, 2017-2025
    • Spain Market Landscape Analysis, 2017-2025
  • Latin America Market Landscape Analysis, 2017-2025 (USD Mn)
    • Brazil Market Landscape Analysis, 2017-2025
    • Mexico Market Landscape Analysis, 2017-2025
    • Colombia Market Landscape Analysis, 2017-2025
  • Asia pacific Market Landscape Analysis, 2017-2025 (USD Mn)
    • Japan Market Landscape Analysis, 2017-2025
    • China Market Landscape Analysis, 2017-2025
    • India Market Landscape Analysis, 2017-2025
  • Middle East & Africa Market Landscape Analysis, 2017-2025 (USD Mn)
    • Saudi Arabia Market Landscape Analysis, 2017-2025
    • South Africa Market Landscape Analysis, 2017-2025
 

Chapter 8: Pricing Analysis

 
  • Optimal Price Points (OPP), Indifference price points (IPP) and Range of Acceptable Prices and (RAP) of leading brands by Region- 2017
  • North America Pricing Analysis (OPP, IPP, and RAP - 2017)
    • U.S. Pricing Analysis-2017
    • Canada Pricing Analysis-2017
  • Europe Pricing Analysis (OPP, IPP, and RAP - 2017)
    • UK Pricing Analysis-2017
    • Germany Pricing Analysis-2017
    • France Pricing Analysis-2017
    • Italy Pricing Analysis-2017
    • Spain Pricing Analysis-2017
  • Latin America Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Brazil Pricing Analysis-2017
    • Mexico Pricing Analysis-2017
    • Colombia Pricing Analysis-2017
  • Asia Pacific Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Japan Pricing Analysis-2017
    • China Pricing Analysis-2017
    • India Pricing Analysis-2017
  • Middle East Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Saudi Arabia Pricing Analysis-2017
    • South Africa Pricing Analysis-2017

Chapter 9: Hepatitis Therapeutics Pipeline Analysis

  • Executive Summary
  • Late Stage Pipeline analysis
  • Key R&D trends

Chapter 10: Hepatitis Therapeutics Merger & Insights (M&A)

  • Major licensing deals
  • Factors driving M&A in Epigenetics market
  • Key trends and future outlook

Chapter 11: Hepatitis Therapeutics Regulatory Landscape

  • Regulatory Landscape by Region (U.S., Europe, and Row)
  • Patent Landscape by Region (U.S., Europe, and Row)

Chapter 12: Competitive Dynamics

  • Sanofi
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Bristol-Myers Squibb Co
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • GSK
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  •  AbbVie
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  •  Merck & Co., Inc.,
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  •  Johnson & Johnson
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Gilead Lifesciences
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Vertex Pharmaceuticals
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Schering
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
 

List of Tables

 
  • TABLE 1 Hepatitis Therapeutics Market- Industry Snapshot & Key Buying Criteria, 2017 - 2025
  • TABLE 2 Global Epigenetics Market, 2017 – 2025
  • TABLE 3 Global Hepatitis Therapeutics Market Analysis by Product-2017
  • TABLE 4 Global Hepatitis Therapeutics Market Analysis by Technology -2017
  • TABLE 5 Global Hepatitis Therapeutics Market Analysis by Application-2017
  • TABLE 7 Global Hepatitis Therapeutics Market Analysis by Geography-2017
  • TABLE 8 Global Hepatitis Therapeutics Market Analysis by Leading Brands-2017
  • TABLE 9 Hepatitis Therapeutics Market- Key market driver analysis
  • TABLE 10 Hepatitis Therapeutics Market- Key market restraint analysis
  • TABLE 11 North America Market Epigenetics Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 12U.S. Hepatitis Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 13 Canada Hepatitis Therapeutics Market Landscape Analysis, 201-2025
  • TABLE 14 Europe Hepatitis Therapeutics Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 15 U.K Hepatitis Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 16 Germany Hepatitis Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 17 France Hepatitis Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 18 Italy Hepatitis Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 19 Spain Hepatitis Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 20 Latin America Hepatitis Therapeutics Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 21 Brazil Hepatitis Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 22 Mexico Hepatitis Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 20 Colombia Hepatitis Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 21 Asia pacific Hepatitis Therapeutics Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 22 Japan Hepatitis Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 23 China Hepatitis Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 24 India Hepatitis Therapeutics Market Landscape Analysis, 2017-2025
  • TABLE 25 North America Pricing Analysis
  • TABLE 26 North America Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 27 U.S. Pricing Analysis-2017
  • TABLE 28 Canada Pricing Analysis-2017
  • TABLE 29 Europe Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 30 U.K Pricing Analysis-2017
  • TABLE 31 Germany Pricing Analysis-2017
  • TABLE 32 France Pricing Analysis-2017
  • TABLE 33 Italy Pricing Analysis-2017
  • TABLE 34 Spain Pricing Analysis-2017
  • TABLE 35 Latin America Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 36 Brazil Pricing Analysis-2017
  • TABLE 37 Mexico Pricing Analysis-2017
  • TABLE 38 Colombia Pricing Analysis-2017
  • TABLE 39 Asia Pacific Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 40 Japan Pricing Analysis-2017
  • TABLE 41 China Pricing Analysis-2017
  • TABLE 42 India Pricing Analysis-2017
  • TABLE 43 Middle East Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 44 Saudi Arabia Pricing Analysis-2017
  • TABLE 45 South Africa Pricing Analysis-2017
 

List of Figures

 
  • 1 Hepatitis Therapeutics Market Segmentation
  • 2 Market Size & Growth Prospects
  • 3 Leading Brand Dynamics
  • 4 Penetration & Growth Prospects
  • 5 Industry Analysis – Porter’s
  • 6 Hepatitis Therapeutics Market– PESTEL Analysis
  • 7 Hepatitis Therapeutics Market Share by Product Type, 2017 & 2025
  • 8 Hepatitis Therapeutics Market Share by Technology Type, 2017 & 2025
  • 9 Hepatitis Therapeutics Market Share by Application Type, 201 & 2025
  • 10 Hepatitis Therapeutics Market Share by Region, 2017 & 2025
 

Key Insights Addressed:  

  • Defining market size from 2014 to 2017.
  • Estimating market growth till 2025 and consequence market forecast.
  • Identifying market drivers, restraints & future opportunities and allowing decision-maker with a range of possible outcomes and the probabilities that will occur for any choice of action.
  • Market segments and regions that will drive or lead market growth.
  • Defining Optimal Price Point (OPP) which will be accepted and recommended by maximum customers.
  • A bird’s-eye view of the competitive landscape and the key market players.
  • Key strategic growth driver adopted by market players. In-depth analysis of their strategies and implication on competition & growth.
    Key Findings:      
  • The Global Hepatitis Therapeutic market was valued at $ 23.4 Billion in 2017 and is forecast to grow at a modest 3.6 % CAGR between 2018 and 2025, culminating in 2025 global sales of $ 27.8 Billion.
  • Rising viral infection including type A, B, C, D, E and possible G are the major cause of hepatitis. Hepatitis B and C can cause chronic hepatitis. Symptoms of acute hepatitis A include fatigue, flu-like conditions or dark urine whereas chronic hepatitis is mild and non-specific.
  • We are observing increasing deaths due to viral hepatitis globally, 1.34 million deaths in 2015, comparable to deaths caused by tuberculosis and higher than those caused by HIV. However, the number of deaths due to viral hepatitis is increasing over time, while mortality caused by tuberculosis and HIV is declining.
  • We have profiled major players in the market as Sanofi, GSK, Merck & Co., Roche, Bristol-Myers Squibb Company, Gilead, Vertex Pharmaceuticals, Three Rivers Pharma, Schering, Janssen Pharmaceuticals, Schering, Gilead Sciences, Merck Sharp Dohme.

Ameri Research implies a unique methodology of published information and primary research to bring key insights to customer decision making process. Our analytics model helps us to understand the structured and unstructured information from various sources. Key steps involve in the process are as below-

  1. Analyzing Published Information- Access to large pool of paid and unpaid published information via different sources and analyzing market trend.
  2. Setting Foundation- Input from analysis of secondary sources set our foundation to market analysis and helps in setting the scope for further research. Setting the scope involves Ameri Research proprietary statistical model, discussion with industry leaders, internal brainstorming, key discussion pointers from various forums etc.
  3. Need Gap Analysis- Defining the gap between our scope and availability of information.
  4. KOL Panel Discussion- Focused Group Discussion with a structured discussion guide to fine tune the gap and deriving the factors driving/restraining the market trend.
  5. Quantitative Research- Sampling large number of industry players, Education/Research Institutes, Government bodies, NGOs, Individual acclaimed researchers and conducting the primary interview with a structured questionnaire.
  6. Data Triangulation- We apply bottom-up demand approach or top-down estimation or a combined approach to triangulate the data points.
  7. Analyst Comment- Each of our analysts carries large pool of experience from domain perspective and add their value which is directional in nature
global-aesthetic-dermatology-market

To request a free sample copy of this report, please complete the form below verified and secure

We offer complete free customization that addresses client’s need. This includes insights from primary market research and a 60-minute free analyst consultation post report purchase.

This website is secure and your personal details are safe. Privacy policy

Description

The Global Hepatitis Therapeutic market was valued at $ 23.4 Billion in 2017 and is forecast to grow at a modest 3.6 % CAGR between 2018 and 2025, culminating in 2025 global sales of $ 27.8 Billion. Rising viral infection including type A, B, C, D, E and possible G are major cause of hepatitis. Hepatis B and C can cause chronic hepatitis. Symptoms of acute hepatitis A include fatigue, flu like conditions or dark urine where as chronic hepatitis are mild and non-specific.

 

As per Center for Disease Control (CDC), in 2017 reported cases of hepatitis C nearly tripled, reaching 15 years high. Actually 10 times more patients get undetected. Similarly, 1,390 new patients reported with Hepatitis A and 3,370 new cases of Hepatitis B in 2015. We are observing steep rise in cases of hepatitis C in particular in last few years and trend is going to continue. Patients with autoimmune disorder are adding to increase prevalence of hepatitis. Aging population and changing societal behavior adding to this steady increase. Globally, in 2015, an estimated 257 million people were living with chronic HBV infection, and 71 million people with chronic HCV infection.

 

We are observing increasing deaths due to viral hepatitis globally, 1.34 million deaths in 2015, comparable to deaths caused by tuberculosis and higher than those caused by HIV. However, the number of deaths due to viral hepatitis is increasing over time, while mortality caused by tuberculosis and HIV is declining.

 

Global Hepatitis Therapeutic Market to 2025

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Global Hepatitis Therapeutics Products”

 

Estimated Average Hepatitis Therapeutics product cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the world, the Hepatitis Therapeutics products are available at USD XXXX. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.

 

Treatment Insight

 

Hepatitis A- It’s a short-term illness and may not require any medication apart from bed rest and physician order for hydration and nutrition. Hepatitis A vaccine is also available to prevent infection.

Hepatitis B- It’s treated with antiviral medications. These treatments are supposed to continue for several months. It also requires regular physician supervision to ensure if the virus is responding to the treatment. Hepatitis B vaccination available recommended for all newborns.

Hepatitis C- Antiviral medications are usually recommended for the treatment of hepatitis C. Currently there is no vaccination for Hepatitis C.

Hepatitis D- No antiviral medications for the treatment of hepatitis D. Limited improvement noticed with fewer patients with a drug called alpha interferon. It can also prevent by vaccination for Hepatitis B.

Hepatitis E- No specific medication for hepatitis E apart from sufficient rest, water and nutrients.

Some of the U.S. FDA recommended antiviral medicines for the treatment of hepatitis B are as below-

 

Hepatitis B Therapeutic

 

Some of the U.S. FDA recommended antiviral medicines for the treatment of hepatitis C are as below-

 

Hepatitis C Therapeutic

 

We have segmented the market based on the type of hepatitis as Hepatitis A, B, C, D, E, and others.

 

Product Insight

 

We have segmented the market based on medications and vaccines. We will help our client in understanding market segment for individual treatment type if necessary at a premium service.

 

Regional Segmentation

 

North America accounted for over xx% revenue share in 2017. The key reasons attributed to the high share include strong reimbursement framework, technological advancements and government support for R&D and innovation in medical devices sector. Moreover, the presence of high-end hospital and POC and high emphasis on prevention is expected to boost the usage rates over the forecast period.

Asia Pacific is expected to register the maximum CAGR of xx% from 2017 to 2025. The rapid increase in a number of chronic cases, growing healthcare expenditure and skill training, and improvement in reimbursement scenario are expected to favor the high market growth in the region.

 

Top Players & Company Share

 

We have profiled major players in the market as Sanofi, GSK, Merck & Co., Roche, Bristol-Myers Squibb Company, Gilead, Vertex Pharmaceuticals, Three Rivers Pharma, Schering, Janssen Pharmaceuticals, Schering, Gilead Sciences, Merck Sharp Dohme. With recent development, we are observing some unique new players into the market.

 

Market Segmentation

 

Global Hepatitis Therapeutics Market by Disease Types (Revenue, USD Million, 2014- 2025)

  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Hepatitis D
  • Hepatitis E
  • Others

Global Hepatitis Therapeutics Market by Products (Revenue, USD Million, 2014 – 2025)

  • Medications
  • Vaccines

Global Hepatitis Therapeutics Systems Regional Outlook (Revenue, USD Million, 2014- 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • South Africa

Additional information

Price

Single User $3,650, Multiple User $4,650, Enterprise User $6,650